Video recording available here now: https://www.riksdagen.se/sv/webb-tv...motande-av-patienter-med-diagnosen-me_H610263
Haven't seen it myself, but here's a summary https://twitter.com/user/status/1135576493860577280 Microsoft translation: In today's interpellation debate, Minister for Social Affairs blamed @lenahallengren a lack of consensus on diagnostic criteria for not setting up a centre of Excellence FOR ME/CFS. Bad excuse. The Canadian consensus criteria were highlighted in the SBU :s expert report and are used in the Stockholm Region. ETA: SBU = The Swedish Agency for Health Technology Assessment and Assessment of Social Services
Two conferences later in the year from RME. 16th October in Stockholm https://rme.nu/5763-2/ 17th October in Umeå https://rme.nu/konferens-17-oktober-2019-umea/ Both links not in English.
This blog post is about why it might be difficult but sometimes also very important to criticise "the good guys". It's well worth a read. It's relevant not only because of the Montoya news and how it is currently being talked about on social media etc, but also in relation to the situations that during the last few years keep sparking reoccurring conflicts in Swedish ME groups (which does more harm to the ME community: silencing justifiable criticism and continuously sweeping serious problems under the rug, or acknowledging the problems and talking openly about them?). Is this a big source of conflict in other countries too? https://mitteremitage.wordpress.com/2019/06/07/en-elefant-i-rummet/ Google Translate, English ("An Elephant in the Room") (I'd say that's very "politely" put of the blogger... Sadly, people have been silenced, censored, bullied, ostracised and defamed etc, for expressing justifiable criticism.) Google Translate, English ("An Elephant in the Room") https://twitter.com/user/status/1136951756938723328
I agree with the view of the blogger and patient, but not sure how big of a problem this actually is? My opinion is that the climate for (constructive) criticism in all directions overall are quite good, also among “the good guys”. Could be wrong. In Norway there are no clinics, so that kind of solves itself in its peculiar unsatisfactory way. But there surely is room for a lot of improvement on a more general level. I imagine that every ME-patient in contact with the healthcare system have experienced at least one, often several episodes that objectively easily should be categorized as unacceptable.
Danish Medical Journal (Ugeskriftet.dk) has published an article about the status of CFS/ME. It's good to see references to Wilshire et al and Twisk et al, but the authors still suggests that a subset of ME-patients might benefit from GET. They also define ME as a functional disorder.. The recommended treatment modalities for patients with ME / CFS have been centered on graded training and cognitive behavioral therapy. In recent years, the utility of the graded exercise in the treatment of ME / CFS has been questioned.This partly based on the increasing recognition of the metabolic disorders of ME / CFS, and partly based on a critical review of the clinical studies that lay the basis of these forms of treatment [24, 25]. A key issue and basis for great disagreement with the approach to patients is whether we should "spare" or "push" them.We do not have a definitive answer, but suggest that much of the disagreement is based on the fact that a subset of this poorly-defined patient group will benefit from being "pushed" into graded training and cognitive therapy while at the other end of the spectrum will be patients who, at the cellular level, will be harmed by training and therefore must be "spared" [25, 26]. In both groups, symptomatic treatment can be attempted in close collaboration with the patient, where sleep problems, orthostatic intolerance, pain and other key symptoms can be handled carefully according to current guidelines. It is stated that there is currently no evidence-based treatment modalities aimed at the basic disease process in ME / CFS, as this is not known. Myalgisk encefalomyelitis eller kronisk træthedssyndrom google translation: Myalgic encephalomyelitis or chronic fatigue syndrome Summary: Louise Brinth, Henrik Nielsen, Kim Varming, Susanne E Boonen, AC Gonzalez Ebsen, Paula Fernández-Guerra, Anne Sophie Schou, Jesper Mehlsen, Niels Gregersen, Ivan Brandslund & Rikke Katrine Jentoft Olsen: Myalgic encephalomyelitis or chronic fatigue syndrome Ugeskr Læger 2019;181:V08180570 In this review, we discuss the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), which is characterised by extreme mental and physical fatigue with associated symptoms of pain, disturbed sleep, cognitive and autonomic dysfunction, as well as post-exertional malaise. This condition is often preceded by an infection, severe physiological and/or psychological strain. Over the last decades, research has demonstrated mitochondrial, neuroendocrine, immunological, and metabolic perturbations in patients with ME/CFS, giving hope for the development of new biomarkers and new treatment modalities.
Moderator note: Posts discussing the Danish Medical Journal (Ugeskriftet.dk) article have been moved to a new thread here https://www.s4me.info/threads/status-of-cfs-me-2019-brinth-et-al-danish-medical-journal-ugeskriftet-dk.9926/
One of the authors, Mehlsen, has been invited by the Swedish patient organisation RME to give a talk on "Meeting ME/CFS patients in a clinical setting" at their public seminars this fall. Will he be talking about treatment recommendations? If so, will he be recommending GET, like this article of his does? Will he be talking about functional disorders? I wonder why RME choose Mehlsen, out of all the people on the planet, to give this particular talk. Why not one of the more experienced clinicians from one of the Swedish biomedical ME centers, for example? Why someone from another country, a country that has a completely different (arguably much more problematic) clinical approach to ME?
I didn't know Mehlsen, but googling him would suggest no need to worry to much?He was engagede in removing ME from functional disorders in Denmark. He is very clear in this statement at the danish ME association: https://me-foreningen.dk/om-me/informationsmateriale/ Also, I didn't read the article as recommending GET, but initiating the idea that there are patients who should absolutly not do GET and are likely to be harmed. The same argument is beeing introduced here by various people. As a way to get the discusion moving foreward, and opening for seperating ME-patients from the muddle of CFS. edit: words - how do they work? some went missing, some extra
Thank you! I too googled Mehlsen earlier, but those links didn't show up in the search result for me. Instead, I got links to his paper with Per Fink et al The Danish study of Functional Disorders, among other things... Very helpful to get some insight from the perspective of Danish pwME and ME Foreningen, thank you
Oh, and I didn't see that functional disorder paper - that would have worried me too! Don't understand why he is involved in that, but the things I'm finding seems good? He signed this for instance, appealing to the Netherlands: https://www.meaction.net/2018/07/20...ands-to-invest-in-biomedical-research-for-me/
News article about a woman who just got compensation for developing ME after a shot with the flu vaccine Pandemrix. ABC Nyheter: Kvinne fikk ME etter Pandemrix-vaksine - saksøkte staten og vant google translation: Woman got ME after Pandemrix vaccine - sued the state and won Trude Schei from the Norwegian ME Association says in the article: - No matter which vaccine is involved, there is a risk of someone having a serious side effect. But in a societal perspective, the vaccination has great value because it provides protection that makes many very sick. - Therefore, it is a social responsibility to care for those who become ill by the vaccine. I find it very positive that those who have had a negative effect from the vaccine receive compensation, says Schei to ABC News. She thinks that taking care of those who have had serious side effects, along with research on why someone gets these side effects, will increase confidence in the health authorities and the vaccination program.
I have talked to some people who also developed ME after the Pandemrix vaccination. It is all too sad. This article is worth reading in the discussions about vaccines. https://www.spiegel.de/internationa...ine-flu-vaccine-for-politicians-a-656028.html Edit: Politicians in Germany didn´t get Pandemrix. They got another brand that was considered less risky.
The Norwegian ME Association just announced that they are open for applications from Norwegian researchers for clinical trials into symptom relief for sleep difficulties, pain and/or stomach/digestive problems. They have 1.3 million NOK (150 000 USD, 1 18 000 GBP, 132 000 EUR) for this purpose. Announcement: 1 300 000 kroner til forskning på symptomlindring google translation: 1 300 000 NOK for research on symptom relief
Sometimes I wonder if that's one of the reasons we are suppressed, that this may be one of the consequences of vaccination and the anticipated disaster it would cause. For the record I would still be 100% in favor of mass vaccination, even if it were the main culprit. It's still entirely worth it on balance. But, you know, don't freaking hang us out to dry and actually work on fixing it. We can have both, it's not a mutually exclusive choice. I don't give it big odds, probably just one factor out of many. I've had many immune reactions in my life, including a vaccine and antibiotics. It's probably more of an accumulation of things that just leave the system in a sustained state of emergency. Because overall it would be 100x more damaging if it turned out to be an important factor that had been suppressed. Antivaxxers would jump on it and it would wreak havoc on public confidence in health care systems. It would likely add even more to fuel the fire than the Wakefield paper.
That’s great. Well done to all who donated, fundraised or in some way were involved. I think I would have preferred the money wasn’t restricted to clinical trials/symptoms relief. I think it’s important to work out the biology so we have a better understanding of what is involved, what drugs might be required, what objective measures could be used to measure clinical response, etc.
